Lutathera® Therapy for Rare Pancreatic and Gastrointestinal Tumors

Lutathera® is an advanced treatment for pancreatic and gastrointestinal neuroendocrine tumors (NETs), a rare type of cancer that often begins in the intestinal tract and can spread to other organs, such as the liver. These tumors can cause severe symptoms, including chronic diarrhea, and require specialized care.

Lutathera combines Lutetium 177, a radioactive element, with Dotatate, a compound that targets somatostatin receptors on neuroendocrine tumor cells. This targeted therapy, known as peptide receptor radionuclide therapy (PRRT), delivers radiation directly to the cancer cells while minimizing damage to surrounding healthy tissue.

How It Works

The treatment involves four intravenous (IV) infusions, administered every two months. Clinical trials have shown that Lutathera can significantly extend survival and improve quality of life by reducing symptoms and slowing disease progression. Studies report a 48 percent reduction in the risk of death and a 79 percent reduction in the risk of disease progression.

Lutathera therapy requires a coordinated effort from a multidisciplinary team, including medical oncologists, nuclear medicine specialists, nurses and pharmacists, to ensure safe and effective treatment.